Epidemiological studies have clearly established human papilloma-virus (HPV) infection as the central cause of invasive cervical cancer (ICC). This is the second most common cancer among women worldwide and the most common female cancer in large areas of the developing world where an estimated 80% of new cases arise ([Parkin *et al*, 1999](#bib27){ref-type="other"}). Studies in 22 countries, coordinated by the International Agency for Research on Cancer (IARC), identified HPV DNA in almost all (99.7%) (of about 1000) cases of cervical cancer ([Walboomers *et al*, 1999](#bib37){ref-type="other"}).

Approximately 40 distinct HPV types are known to infect the genital tract and epidemiological studies to date suggest that at least 14 of these, called oncogenic or high-risk (HR) types, are significantly associated with progression to ICC ([Bosch *et al*, 1995](#bib4){ref-type="other"}). Most of these HR types are phylogenetically related to either HPV16 (31, 33, 35, 52 and 58) or HPV18 (39, 45, 59 and 68) ([Chan *et al*, 1995](#bib41){ref-type="other"}). Limited evidence suggests that their distribution may vary by region ([Bosch *et al*, 1995](#bib4){ref-type="other"}).

HPV vaccines hold great promise to reduce the global burden of ICC any potential vaccine be multivalent since prior infection with one type does not appear to decrease the risk of infection by another HPV type ([Koutsky *et al*, 2002](#bib42){ref-type="other"}; [Combita *et al*, 2002](#bib9){ref-type="other"}; [Liaw *et al*, 2001](#bib19){ref-type="other"}). In this however, to collate all relevant published data to identify the most prevalent HPV types associated with ICC worldwide and within five geographic regions.

Materials and methods
=====================

Study selection
---------------

Source material was selected from citations listed in *Medline* and *ISI Current Contents* databases and from references cited in the selected papers. Key search terms included: cervical cancer, HPV, human, female, and polymerase chain reaction (PCR). The review was limited to studies that included a minimum of 20 ICC cases; carcinomas *in situ* were excluded. Studies had to provide a clear description of the use of PCR-based assays to identify HPV DNA. Studies using nonamplified hybridisation methods only were excluded based on the reduced sensitivity of such methods in comparison to PCR ([Gravitt *et al*, 1991](#bib12){ref-type="other"}; [Schiffman *et al*, 1991](#bib33){ref-type="other"}; [Guerrero *et al*, 1992](#bib13){ref-type="other"}). Furthermore, articles were only included if type-specific prevalence of at least one HPV type other than HPV6, 11, 16 or 18 was reported. For articles where study methods suggested that additional type-specific data were available, these data were requested from the authors ([Yang *et al*, 1997](#bib40){ref-type="other"}; [Eluf-Neto *et al*, 1994](#bib11){ref-type="other"}; [Chaouki *et al*, 1998](#bib7){ref-type="other"}; [Meyer *et al*, 1998](#bib21){ref-type="other"}; [Chen *et al*, 1999](#bib8){ref-type="other"}; [Lin *et al*, 2001](#bib20){ref-type="other"}). If data or data subsets had been published in more than one article, only the publication with the largest sample size was included.

Data abstraction
----------------

For each study, the following key information was extracted: country of sample; sample size; mean age; study year; distribution of cases by histological type; type of cervical specimen (e.g., fresh/fixed biopsies or exfoliated cells) and PCR primers used to detect HPV positive samples; type-specific and overall prevalence of HPV infection. Where available, data on HPV-specific prevalence were extracted independently for squamous cell carcinoma (SCC) and for adeno- and adenosquamous carcinoma (henceforth collectively termed ADC). Where histology-specific HPV prevalence was not reported, cases were classified as being of 'unspecified' histology. Each study was classified into one of five geographical regions: Africa, Asia, Europe, North America and Australia, or South and Central America. For studies comparing HPV prevalence across regions ([Munoz *et al*, 1992](#bib22){ref-type="other"}; [Bosch *et al*, 1995](#bib4){ref-type="other"}; [Sebbelov *et al*, 2000](#bib35){ref-type="other"}), data were separated into their regional components.

Studies included
----------------

Of studies published up to February 2002 on *Medline* identified by our search criteria, 82 qualified for inclusion (no additional studies were included from *ISI Current Contents*). Three studies were conference abstracts containing the detailed information required for inclusion ([Illades-Aguiar *et al*, 2000](#bib17){ref-type="other"}; [Nindl *et al*, 2001](#bib24){ref-type="other"}; [Rabelo-Santos *et al*, 2001](#bib30){ref-type="other"}). In the course of contacting authors, additional data became available for two studies expanded since the original publication ([Burger *et al*, 1996](#bib6){ref-type="other"}; [Andersson *et al*, 2001](#bib1){ref-type="other"}). Detailed information on the design of each of the 85 included studies is listed in the [appendix](#app1){ref-type="app"}.

Estimation of type-specific prevalence
--------------------------------------

HPV prevalence data were expressed as percentages of all cases tested for HPV. Multiple infections (3.7% of all ICC cases) were separated into constituent types, thus type-specific prevalence represents that in either single or multiple infections. Cases with specimens considered to be inadequate for PCR testing were excluded. Type-specific prevalence is presented for the 18 most common HPV types as identified by this review (HPV types 6, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 70, 73 and 82 also known as MM4, W13B or IS39) in order of descending prevalence for each subgroup analysis. Consensus PCR primers My09/11 ([Bernard *et al*, 1994](#bib3){ref-type="other"}), GP5^+^/6^+^ ([Chaouki *et al*, 1998](#bib7){ref-type="other"}) and SPF10 ([Kleter *et al*, 1999](#bib18){ref-type="other"}) were considered to amplify all 18 HPV types, L1C1/L1C2 ([Nakagawa *et al*, 1996](#bib23){ref-type="other"}) to amplify all types, but HPV73 and 82, GP5/6 to amplify types 6, 11, 16, 18, 31, 33, 35 and 45 only ([Roda Husman *et al*, 1995](#bib31){ref-type="other"}), and pU1M/2R ([Harima *et al*, 2002](#bib14){ref-type="other"}) to amplify types 6, 16, 18, 31, 33, 35, 52, 56, 58 and 59 only. For other consensus and type-specific PCR primers, only those HPV types specified in the individual reports were considered amplifiable. For HPV-specific prevalence, only studies testing for a particular HPV type contribute to the analysis for that type, and therefore sample size varies between the type-specific analyses.

Statistical analyses
--------------------

Sources of variation in overall HPV prevalence were investigated by unconditional multiple logistic regression analysis ([Breslow and Day, 1980](#bib5){ref-type="other"}). The final model included the following sources of variation: geographical region, histological type of ICC, type of specimen for HPV DNA testing, and type of PCR primers used. Mean age and study year were found not to be significantly related to overall HPV prevalence. Adjustment of overall HPV prevalence for these variables was done using the *adjust* command in Stata version 7.0, based on probability estimates from the logistic regression model. Confidence intervals for overall HPV prevalence were calculated assuming the nonindependence of cases within the same study using the *cluster* option in Stata ([White, 1980](#bib38){ref-type="other"}). *P*-values comparing the prevalence of particular HPV types in subsets of ICC cases refer to *χ*^2^ tests.

Results
=======

Meta-analysis of overall HPV prevalence
---------------------------------------

A total of 10 058 ICC cases from the 85 identified studies were included in this meta-analysis of HPV prevalence ([Table 1](#tbl1){ref-type="table"}Table 1Region- and histology-specific distribution of included studies and ICC cases    **Number (%) of cases with histology-specific HPV dataRegionNo. of studiesCountries representedNo. of casesSCCADCUnspecified**Africa6Algeria, Benin, Guinea, Mali, Morocco, Senegal, South Africa, Tanzania, Uganda609204 (33.5)21 (3.4)384 (63.1)Asia28Mainland China, India, Indonesia, Japan, Korea, Malaysia, Philippines, Taiwan, Thailand30912273 (73.5)381 (12.3)437 (14.1)Europe32Austria, Czech Republic, Denmark, Finland, France, Germany, Greece, Greenland, Holland, Hungary, Ireland, Italy, Norway, Poland, Russia, Sweden, UK33362010 (60.3)603 (18.1)723 (21.7)North America and Australia13Australia, Canada, USA1562914 (58.5)450 (28.8)198 (12.7)South and Central America12Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Honduras, Mexico, Panama, Paraguay, Peru1460424 (29.0)53 (3.6)983 (67.3)Total85 10 0585825 (57.9)1508 (15.0)2725 (27.1)[^1]). A majority of cases came from studies performed in Asia (31%) and Europe (33%), with African studies representing the smallest proportion of cases (6%). HPV prevalence was reported stratified by histological type for 73% of the cases: 5825 SCC cases and 1508 ADC cases. In total, 12 studies included only SCC and seven studies included only ADC.

Adjusted overall HPV prevalence ranged from 79.3% in Asia to 88.1% in North America and Australia, but did not differ significantly between regions ([Table 2](#tbl2){ref-type="table"}Table 2Prevalence of HPV by region, histological type, HPV DNA specimen and PCR primers used**VariableNo. of studiesNo. of casesCrude HPV prevalence (%)Adjusted^a^ HPV prevalence (%)95% confidence intervals***Region* Africa660988.886.5(76.4--92.7) Asia28309183.179.3(73.7--84.0) Europe32333685.986.7(82.5--90.0) North America and Australia13156287.588.1(83.6--91.5) South and Central America12146089.387.7(83.1--91.2)      *Histological type* Squamous cell carcinoma47582586.987.3(84.8--89.5) Adeno(squamous) carcinoma45150876.776.5(72.3--80.3) Unspecified48272589.089.2(85.1--92.3)      *HPV DNA specimen* Fixed biopsies34332484.383.3(78.9--86.9) Fresh biopsies27399288.487.8(84.9--90.2) Unspecified biopsies849687.187.2(82.3--90.9) Cervical exfoliated cells13144480.178.9(68.5--86.5) Cells and biopsies380293.592.5(87.3--95.7)      *Primers* MY09/1131435585.983.3(80.1--86.0) GP5/6650680.877.8(64.9--87.0) GP5+/6+14168192.290.1(85.0--93.6) SPF10327596.797.2(87.9--99.4) PU1M/2R637680.979.4(68.8--87.0) L1C1/C2565591.288.0(77.2--94.1) Combination9135188.486.4(77.9--92.0) Other416684.389.3(75.2--95.9)TS-PCR only769373.674.7(63.8--83.2)[^2]). HPV DNA was significantly less likely to be detected in ADC (76.5%) than in SCC (87.3%) (*P*\<0.001). DNA detection in ICC of unspecified histology (89.2%) was similar to that in SCC.

Adjusted HPV prevalence was significantly higher from studies testing both cells and biopsies for HPV DNA (92.5%) than from studies testing either cervical exfoliated cells (78.9%) or fixed biopsies (83.3%) only. For PCR primers, highest HPV prevalence was obtained in studies using SPF10 primers (97.2%) and the lowest in studies using type-specific PCR (TS-PCR) only (74.7%). Adjusted overall HPV prevalence varied between 77.8 and 90.1% for other primer sets, but these differences were not statistically significant.

Meta-analysis of HPV type-specific prevalence
---------------------------------------------

Owing to their similar overall and type-specific HPV prevalence, ICC of unspecified histology were combined with SCC for comparison of HPV type-specific prevalence by histological type ([Figure 1](#fig1){ref-type="fig"}Figure 1Type-specific prevalence of HPV in 10 058 worldwide cases of invasive cervical cancer by histological type.). The most common HPV types identified were, in order of decreasing prevalence, HPV16, 18, 45, 31, 33, 58, 52, 35, 59, 56, 6, 51, 68, 39, 82, 73, 66 and 70. Other HPV types were detected in no more than 0.2% of ICC cases. There was considerable variation in HPV-specific prevalence between SCC and ADC. HPV16 was identified more often in SCC (55.2%) than in ADC (31.3%) (*P*\<0.001). The same was found for the HPV16 phylogenetically related types 31, 33, 52 and 58 (*P*\<0.001), but not 35. Conversely, HPV18 was more prevalent in ADC (37.7%) than in SCC (12.3%) (*P*\<0.001). The HPV18 phylogenetically related type 45 was also more prevalent in ADC (5.8%) than in SCC (3.4%) (*P=*0.04).

Comparison of HPV-specific prevalence in SCC by region is shown in [Figure 2](#fig2){ref-type="fig"}Figure 2Type-specific prevalence of HPV in 8550 cases of squamous cell and unspecified cervical carcinoma by region.. In SCC, HPV16 was the predominant type in all regions studied, varying from 45.9% in Asia to 62.6% in North America and Australia. HPV18 was found consistently in 10--14% of SCC cases. In most regions, HPV45 (2--8%), 31 (2--7%) and 33 (3--5%) were the most prevalent types in SCC after types 16 and 18. In cases from Africa, the prevalence of HPV45 (8.0%) was more than twice that of either 31 (2.7%) or 33 (3.2%). In cases from Asia, HPV58 (5.8%) and 52 (4.4%) were found more commonly than HPV45, 31 and 33. Other HPV types varied considerably in their prevalence from region to region, but accounted for no more than 2% of ICC cases from any region.

Sufficient ADC-specific data existed for the comparison of HPV-specific prevalence across Asia, Europe and North America and Australia ([Figure 3](#fig3){ref-type="fig"}Figure 3Type-specific prevalence of HPV in 1508 cases of adeno- and adenosquamous cervical carcinoma by region.). HPV18 was the predominant type (37.7%), found consistently in 37--41% of ADC cases in these regions, with HPV16 accounting for a smaller proportion (26--36%). HPV45 was the third most prevalent in each region, present in 5--7% of ADC cases *vs* only in 2--4% of SCC cases from these regions. The HPV16 phylogenetically related types 31, 33, 52 and 58 (but not 35) were all less prevalent in ADC cases than in SCC cases from each region.

Discussion
==========

Two-thirds of ICC cases included in this meta-analysis were associated with HPV16 (51.0%) or 18 (16.2%) infection. However, more than 16 other HPV types were also associated with ICC, of which the most prevalent were types 45, 31, 33, 58 and 52 (collectively accounting for 18.3% of cases). The HPV16 family of viruses were more commonly found in SCC than ADC, whereas the HPV18 family were more common in ADC.

Geographical region
-------------------

Overall detected HPV prevalence varied little between geographical regions (83--89%), but was low compared to the almost 100% HPV prevalence identified in studies using the most sensitive HPV detection methods ([Walboomers *et al*, 1999](#bib37){ref-type="other"}). This reflects the fact that many studies used HPV DNA detection strategies of suboptimal sensitivity. When comparing prevalence by region and histology, we attempted to take account of alternative HPV DNA sources and PCR primers by adjustment. However, it is not known to what extent other unknown sources of variation such as sample storage conditions, specific PCR conditions and quality of histopathology may affect these comparisons. Residual differences in prevalence between regions could also be because of the yet unknown HPV types not amplified by the existing PCR primers.

There were many similarities in HPV type-specific distribution across the regions studied. In SCC, HPV16 was clearly the predominant type varying from 45.9% in Asia to 62.6% in Europe, with HPV18 being found consistently in 10--14% of the cases. Other rarer types appeared to vary in their distribution. In most regions, HPV45, 31 and 33 were the third, fourth and fifth most common genotypes, although not necessarily in that order. Asia appeared to be different with a larger proportion of cancers associated with HPV58 and 52, as highlighted by a recent study in China of 786 cases in which HPV58 and 52 were the third (10%) and fourth (9%) most common genotypes in ICC ([Wong *et al*, 2000](#bib39){ref-type="other"}). Other types in SCC were too rare to make inferences on region-specific variations.

Histological type of ICC
------------------------

This meta-analysis shows that overall HPV prevalence detected in ADC was significantly lower than that detected in SCC. This intriguing finding does not appear to be because of differences with respect to region or HPV detection methods as it persisted even after adjusting for these factors. ADC arises from tissue deeper in the interior of the cervix uteri than SCC, and it has been reported to be more difficult to appropriately sample exfoliated cells of ADC than SCC ([Sasieni and Adams, 2001](#bib32){ref-type="other"}). However, most HPV detected in the present review was based on biopsy specimens (77%). A proportion of cervical ADC could be misclassified ADC arising from the endometrium or other rare histological variants of ADC, for example, clear cell and mesonephric, which have been suggested to be HPV-independent ([O\'Leary *et al*, 1998](#bib25){ref-type="other"}; [Pirog *et al*, 2000](#bib28){ref-type="other"}).

Whereas HPV16 was the most common type in SCC followed by HPV18, the situation was reversed in ADC where HPV18 was the most common type, followed closely by HPV16. This difference has been described independently by many of the studies in this analysis and by studies outside the scope of this review ([IARC, 1995](#bib16){ref-type="other"}). Compared to HPV16, HPV18 has been shown to be associated with increasing oncogenic potential in cell culture ([Barbosa and Schlegel, 1989](#bib2){ref-type="other"}), as well as a more rapid transition to malignancy ([Burger *et al*, 1996](#bib6){ref-type="other"}) and a poorer prognosis of cancer patients ([Nakagawa *et al*, 1996](#bib23){ref-type="other"}; [Hildesheim *et al*, 1999](#bib15){ref-type="other"}; [Schwartz *et al*, 2001](#bib34){ref-type="other"}). Given the fact that columnar tissue giving rise to ADC is less accessible, and possibly less susceptible to HPV infections, than the squamous tissue of SCC, the establishment of ADC may require a relatively more aggressive infection. In addition to HPV16 and 18, this large meta-analysis facilitated the identification of differences for some rarer phylogenetically related types: the HPV16-related types 31, 33, 35, 52, and 58 were more prevalent in SCC (15.0% collectively) than in ADC (4.4% collectively); and HPV18-related 45 was more prevalent in ADC (5.8%) than SCC (4.2%). All these differences were seen consistently in all regions where the comparison was possible.

For all regions where histological comparison was possible, the ratio of ADC to SCC was higher than that reported by cancer registries ([Parkin *et al*, 1997](#bib26){ref-type="other"}). For example, ADC represent 23.1% of histologically verified cases from Europe in this study, but only 15.3% of ICC cases reported to European cancer registries ([Parkin *et al*, 1997](#bib26){ref-type="other"}). Since all seven studies of only ADC cases were from Europe, Japan or USA, ADC is over-represented in this meta-analysis, particularly in developed countries. No material differences in results were observed when SCC was compared with cancers of unspecified histology.

Study limitations
-----------------

The different PCR primers employed by the studies covered in this analysis varied in their overall detection of HPV DNA, with the highest prevalence being obtained with SPF10 and GP5+/6+ primers, supporting findings from previous studies ([Davies *et al*, 2001](#bib10){ref-type="other"}). Such variation is partly because of known differences in the range of HPV DNA types amplifiable by each primer set, and this was taken into consideration when estimating type-specific prevalence. However, there is also evidence that not all primer sets amplify individual HPV types with the same sensitivity ([Qu *et al*, 1997](#bib29){ref-type="other"}; [Kleter *et al*, 1999](#bib18){ref-type="other"}), and such differences are a potential source of bias in this analysis.

The type-specific prevalence reported for each individual type includes that in multiple infections, which were reported in a total of 3.7% of our ICC cases. Since many of the included studies tested for only a subset of HPV types, many multiple infections will have been missed. Hence, this meta-analysis was unable to estimate how often individual HPV types were found in the presence of other types, which limits the conclusions that can be made about individual HPV-type oncogenicity. In particular, a large proportion of cases positive for HPV6, which is not thought to be oncogenic, may be coinfected with an undetected HR HPV type.

The cases included in this meta-analysis are not representative of the worldwide distribution of ICC. The proportion of cases contributed by Africa (6.1%) and Asia (30.7%) in this study under-represent their proportional burdens of worldwide cervical cancer, which are 14.1 and 49.4%, respectively ([Parkin *et al*, 1999](#bib27){ref-type="other"}). In contrast, the proportion of cases contributed by Europe (33.2%) and North America and Australia (15.5%) over-represent their proportional burdens, which are 15.7 and 4.4%, respectively. Adjustment of type-specific prevalence in all ICC cases ([Figure 1](#fig1){ref-type="fig"}) by weighting each region according to their cancer burden, however, did not materially effect the results, highlighting the general similarity of HPV-type distribution across regions (data not shown).

Furthermore, the cases in this meta-analysis were not drawn uniformly from across each region. Large areas have not been included (e.g., the Middle East and Indian subcontinent in Asia), while other specific populations such as Japan in Asia are over-represented. There is also evidence of inter-regional variation in HPV-type distribution; the high prevalence of HPV52 and 58 in Asia is more apparent in cases from China/Korea/Japan than in those from South East Asia. Hence, for the comparison of alternative regional groupings, HPV-specific prevalence is presented by study in the [Appendix](#app1){ref-type="app"} ([Table A1](#tbla1){ref-type="table"}).

Given that HPV is considered a virtually necessary cause of ICC, we further examined results restricted to HPV DNA-positive cases. This increased type-specific prevalence by a factor of ≈1.1 consistently for each HPV type, with no impact on the relative distribution of HPV types. However, given that many of the PCR systems used by the included studies amplify only a subset of HPV types, many HPV-'negative' cases may actually be infected with other, unascertained, HPV types. Thus, we did not consider it appropriate to restrict to HPV-positive cases when comparing type-specific prevalence across studies where PCR methodology differed considerably.

However, in order to make a broad overall estimate if one does assume that, HPV DNA should be detectable in 100% of ICC and that the distribution of undetected types in HPV-negative cases is similar to that in positive cases, this meta-analysis suggests that vaccinating against HPV16 and 18 should prevent over 70% of worldwide ICC. However, a worldwide vaccine against only HPV16/18 may prevent a larger proportion of ICC in Europe, North America and Australia (≈75%), than in Africa, Central and South America and Asia (59--64%), where a larger proportion of ICC cases were associated with other HPV types. Although this study identifies at least 18 HPV types associated with ICC from around the world, the most important type after HPV16 and 18 appears to be HPV45, followed by types 31, 33, 58 and 52, the relative importances of which vary by region.

The work reported in this paper was undertaken by Dr Gary Clifford during the tenure of an IARC Postdoctoral Fellowship from the International Agency for Research on Cancer. We thank the Vaccine Development team (VAD) of the Department of Vaccines and Biologicals of the World Health Organization, Geneva and Swiss Bridge (Award 2001) who supported and contributed to the funding of this work. We are grateful to Dr Teresa Aguado, Coordinator, VAD and Dr Sonia Pagliusi, Scientist, VAD for their critical comments during the preparation of the manuscript, as well as to Dr Rolando Herrero. We also thank those authors who made additional data available from their published studies.

A comparison of alternative regional groupings, HPV prevalence is presented by the study in Table AI

Table AIStudy methods and prevalence of human papillomavirus by study and by region       **HPV prevalence (% of all cases tested)First authorReferenceCountryHPV DNA sourcePCR primers used to identify all HPV +veNo. casesSCC (incl. unspec)/ADCAny16184531335852355956516683982736670***Africa* Bosch FX*JNCI* (1995)Algeria, Benin, Guinea, Mali,Uganda,TanzaniaFresh biopsiesMy09/11186186/089.842.517.712.42.72.72.72.22.20.03.21.10.02.2 0.5 0.0  Bayo S*Int J Epidemiol* (2002)MaliFresh biopsiesGP5+/6+6565/096.947.712.310.80.01.53.10.01.50.00.06.20.00.00.0 3.10.0  Chaouki N*Int J Cancer* (1998)MoroccoExfol. cellsGP5+/6+186173/1394.667.712.44.83.82.70.01.10.51.60.50.00.50.00.00.00.00.50.0 Lin P*Cancer Epid Biomark Prev* (2001)SenegalExfol. cellsMY09/11 +HMB015151/064.737.37.89.80.05.92.03.92.00.02.00.02.00.00.0 0.00.0  Williamson AL*J Med Virol* (1994)South AfricaFresh biopsiesMY09/116860/880.945.61.51.55.95.9      0.0       ter Meulen J*Int J Cancer* (1992)TanzaniaExfol. cellsGP 5/65353/088.737.732.15.70.01.9             **Region subtotal**    **609588/2188.850.214.17.92.63.11.61.61.40.61.61.20.40.80.00.30.70.20.0**                          *Asia*Huang S*Int J Cancer* (1997)ChinaFresh biopsiesMY09/114035/587.527.530.00.00.00.027.527.50.00.00.00.00.00.00.00.0 0.00.0Lin QQ*Int J Cancer* (1998)ChinaFresh/fixed biopsiesMY09/11, GP5+/6+7777/093.548.15.21.32.63.918.25.20.02.60.00.010.40.00.00.00.00.01.3Lo KWK*Gynecol Obstet Invest* (2001)ChinaFresh biopsiesMY09/11121107/1478.548.811.60.00.85.06.60.80.00.00.80.00.00.00.0 0.00.00.0Peng H*Int J Cancer* (1991)ChinaExfol. cellsTS-PCR only10192/934.731.7   3.0             Stephen AL*Int J Cancer* (2000)ChinaFixed biopsiesGP5+/6+ of TS-PCR neg samples only3424/1088.261.88.82.90.02.92.90.00.02.90.00.00.00.00.0 0.00.0 Munirajan AK*Gynecol Oncol* (1998)IndiaFresh biopsiespU-1M/pU-2R4343/069.853.59.3 0.02.32.30.02.30.00.0 0.0      Bosch FX*JNCI* (1995)Indonesia, Philippines, ThailandFresh biopsiesMy09/119898/096.942.931.68.21.02.02.02.01.01.03.10.00.01.0 4.1 0.0 Fujinaga Y*J Gen Virol* (1991)JapanFresh biopsiespU-1M/pU-2R3939/084.648.712.8 5.15.17.72.6    0.0      Harima Y*Int J Radiat Oncol Biol Phys* (2002)JapanFresh biopsiespU-1M/pU-2R8479/576.226.24.8 2.42.47.12.40.00.00.0 1.2      Kashiwabara K*Acta Pathol Japan* (1992)JapanFixed biopsiesL1C1/C29368/2558.148.46.5 0.01.10.03.2    0.0      Maki H*Jpn J Cancer Res* (1991)JapanBiopsiesL1 PCR2929/082.844.820.7  6.96.96.9    0.0      Nagai Y*Am J Clin Oncol* (2001)JapanExfol. cellsL1C1/C2293239/5485.325.33.1 3.84.13.1 1.7          Nakagawa S*Cancer* (1996)JapanFresh biopsiesL1C1/C2 +C2M146116/3088.437.718.50.72.16.28.210.32.10.00.00.70.02.10.0  0.00.7Nawa ACancer (1995)JapanFresh/fixed biopsiesE6C1/C22323/087.073.913.0  0.0             Saito J*Gynecol Obstet Invest* (2000)JapanFixed biopsiespU-1M/pU-2R6666/075.834.812.1  10.61.56.1           Sasagawa T*Cancer EpidBiomark Prev* (2001)JapanExfol. cellsLCR-E78472/1289.342.914.31.26.01.23.610.71.20.00.04.81.20.00.0 0.00.00.0Yamakawa Y*Gynecol Oncol* (1994)JapanFixed biopsiesTS-PCR only640/6467.232.839.1 1.60.0  7.8   0.0      Hwang T*J Korean Med Sci* (1999)KoreaExfol. cellspU-1M/pU-2R4139/292.736.69.8 7.39.817.17.32.4          Kim KH*Yonsei Med J* (1995)KoreaFixed biopsiesWD72/76 + WD66/67/1543030/070.053.316.7 0.00.0             Yadav M*Med J Malaysia* (1995)MalaysiaFresh biopsiesMY09/112323/095.773.965.2 13.04.3             Ngelangel C*JNCI* (1998)PhilippinesFresh biopsies+exfol. cellsGP5+/6+356323/3393.538.825.612.90.60.02.52.80.02.00.62.50.00.60.30.30.31.10.0Chen SL*Cancer* (1993)TaiwanFresh biopsiesL1C1/C2, E6C1/C2/C34340/372.146.54.7 0.02.32.32.3    0.0      Chen TM*Int J Cancer* (1994)TaiwanFresh biopsiesMY09/11, pU-1M/pU-2R433382/5179.046.212.2  6.5      0.0      Lai HC*Int J Cancer* (1999)TaiwanFresh biopsiesMY09/119487/786.247.98.50.02.14.318.12.10.00.00.00.00.01.10.00.00.00.00.0Yang YC*Gynecol Oncol* (1997)TaiwanFixed biopsiesMY09/11 of TS-PCR neg samples only136120/1683.163.26.6 0.75.1             Bhattarakosol P*J Med Assoc Thai* (1996)ThailandFixed biopsiesMY09/11100100/082.035.017.0  3.0      0.0      Chichareon S*JNCI* (1998)ThailandFresh biopsies+exfol. cellsGP5+/6+377338/3994.754.420.71.61.91.32.72.40.51.60.00.00.50.00.50.00.00.00.5Siritantikorn S*Southeast Asian J Trop Med Public Health* (1997)ThailandLavageMy09/112321/260.956.54.3 4.34.3  0.0   0.0      **Region subtotal**    **30912710/38183.143.415.34.52.03.45.44.21.01.10.41.00.50.50.20.40.10.30.3**                          *Europe*Birner P*Mod Pathol* (2001)AustriaFixed biopsiesGP 5+/6+8686/088.468.68.17.08.141.92.30.01.20.00.00.00.00.00.00.01.20.00.0Baay MFD*J Clin Microbiol* (2001)BelgiumFixed biopsiesGP5+/6+ of TS-PCR neg samples only11595/2087.867.013.01.72.61.70.00.00.00.00.90.00.00.00.00.00.00.90.0Tachezy R*J Med Virol* (1999)Czech RepublicFresh biopsiesMY09/114949/073.559.210.22.04.10.02.00.00.00.00.00.0 0.04.10.00.00.00.0Hording U*APMIS* (1997)DenmarkFixed biopsiesTS-PCR only500/5070.018.052.0  0.0             Sebbelov AM*Microbes Infect* (2000)DenmarkFixed biopsiesGP5/6 of TS-PCR neg samples only3434/085.370.60.00.00.05.9  0.0          Iwasawa A*Cancer* (1996)FinlandFixed biopsiesMY09/11460352/10888.063.525.0  2.6           0.0 Lombard I*J Clin Oncol* (1998)FranceFresh biopsiesTS-PCR of SBH neg samples only297269/2882.850.510.10.31.02.01.00.30.3   0.0 0.0    Riou G*Lancet* (1990)FranceBiopsiesTS-PCR of SBH neg samples only10689/1784.054.716.0  5.7      0.0      Milde-Langosch K*Int J Cancer* (1995)GermanyBiopsiesMY09/115125/2680.451.025.5 3.90.0  0.0   0.0      Nindl I*International Papillomavirus Conference Proceedings* (2001)GermanyFixed biopsiesMy09/117777/089.642.016.0 18.06.00.01.01.0  0.08.0 1.0  1.0 Bosch FX*JNCI* (1995)Germany, Poland, SpainFresh biopsiesMY09/118686/095.365.18.12.35.81.21.23.51.20.02.30.00.03.50.00.0 1.0 Dokianakis DN*Oncol Rep* (1999)GreecePap smearsGP 5/67775/258.42.636.4  3.9             Koffa M*Int J Oncol* (1994)GreeceFixed biopsiesGP 5/63932/776.935.938.5  10.3             Labropoulou V*Sex Transmis Dis* (1997)GreeceFresh biopsiesMY09/113535/097.154.322.90.05.70.00.00.00.00.00.00.00.00.00.00.0 0.0 Sebbelov AM*Microbes Infect* (2000)GreenlandFixed biopsiesGP5/6 of TS-PCR neg samples only3232/084.481.30.00.03.13.1  0.0          Konya J*J Med Virol* (1995)HungaryFresh biopsiesL1C1/C2 +C2M4741/697.955.340.4 2.10.00.02.1    0.0      O\'Leary JJ*J Clin Pathol* (1998)IrelandFixed biopsiesGP5/6, GP1/22020/090.080.010.0  0.0      0.0      Sjyldberg BM*Mod Pathol* (1999)Ireland, SwedenFixed biopsiesGP 5+/6+380/3860.523.726.3 0.00.0             Garzetti GG*Cancer* (1998)ItalyFresh biopsiesGP 5/63232/068.850.015.6 6.30.0  0.0   0.0      Voglino G*Pathologica* (2000)ItalyFixed biopsiesMY09/11, pU1M/2R145120/2598.671.06.9 16.62.1  0.6          Karlsen F*J Clin Microbiol* (1996)NorwayFresh biopsiesMy09/11, GP5+6+, Oli1b/2I, CpI/II361361/098.368.414.1 1.18.3  0.6          Kleter B*J Clin Microbiol* (1999)RussiaFixed biopsiesSPF10180129/51100.064.49.47.83.91.11.71.11.70.02.20.00.00.00.00.00.00.00.0Munoz N*Int J Cancer* (1992)SpainExfol. cellsMY09/11142142/069.045.83.5 3.53.5  1.4   0.0 0.0  0.0 Rodriguez JA*Diag Mol Pathol* (1998)SpainFixed biopsiesGP 5+/6+5454/085.261.17.45.65.61.91.90.00.00.00.00.00.00.00.00.00.00.00.0Andersson S*Eur J Cancer* (2001)SwedenFixed biopsiesMy09/111730/17368.223.936.45.20.60.00.00.00.00.60.00.00.0 0.0    Hagmar B*Med Oncol Tumor Pharmacother* (1992)SwedenFixed biopsiesMY09/117171/074.638.09.9 16.98.5      0.0      Wallin KLNEJM (1999)SwedenFixed biopsiesMY09/11, GP 5+/6+10485/1976.947.125.00.02.95.80.00.00.00.00.00.00.00.00.00.01.00.00.0Zehbe I*J Pathol* (1997)SwedenFixed biopsiesGP 5+/6+4538/795.653.320.06.70.013.32.20.00.0 0.00.00.0      Baay MFD*Eur J Gynaec Oncol* (1996)The NetherlandsFixed biopsiesMY09/11, GP5/6, CpI/II162162/087.761.714.20.61.94.30.60.00.00.00.00.00.00.00.00.0 0.00.0van den Brule AJC*Int J Cancer* (1991)The NetherlandsFresh biopsiesGP5/6 + GP1/25050/0100.084.026.0 4.02.0      0.0      Arends MJ*Hum Pathol* (1993)UKFixed biopsiesTS-PCR only4726/2178.753.229.8  0.0      0.0      Crook T*Lancet* (1992)UKFresh biopsiesTS-PCR of SBH neg samples only2823/589.371.417.9 0.00.0      0.0      Giannudis A*Int J Cancer* (1999)UKFixed biopsiesGP 5+/6+4343/0100.081.49.32.30.04.70.00.00.00.00.00.00.00.02.3  0.0 **Region subtotal**    **33362733/60385.956.017.52.94.24.40.80.50.50.10.60.00.30.40.30.00.30.10.0**                          *North America and Australia*Chen S*Int J Gynecol Obstet* (1999)AustraliaFresh biopsiesMy09/11186153/3391.953.817.24.8               Thompson CH*Gynecol Oncol* (1994)AustraliaFresh/fixed biopsiespU-1M/pU-2R103103/086.465.018.4 2.90.00.0            Duggan MA*Human Pathol* (1995)CanadaFixed biopsiesL1C1/C2 of DBH neg samples only760/7669.735.639.5 0.02.6  0.0   0.0     0.0Bosch FX*JNCI* (1995)USA, CanadaFresh biopsiesMy09/115757/093.057.915.814.05.30.00.00.00.00.03.50.00.01.8 0.0 0.0 Burger RA*JNCI* (1996)USAFresh biopsiesMy09/11401297/10484.851.419.72.22.51.00.51.00.00.00.00.00.50.20.00.00.20.00.0Burnett AF*Gynecol Oncol* (1992)USAFixed biopsiesMy09/112118/3100.071.428.6 42.94.8  19.0   0.0      Ferguson AW*Mod Pathol* (1998)USAFixed biopsiesMY09/11270/2759.325.925.97.4               Paquette RL*Cancer* (1993)USAFresh biopsiesMY09/114528/1793.348.940.0 4.4       0.0      Schwartz SM*J Clin Oncol* (2001)USAFixed biopsiesMY09/11465354/11188.258.523.21.32.43.40.00.00.20.00.00.02.40.00.20.00.20.20.0Sebbelov AM*Microbes Infect* (2000)USAFixed biopsiesGP5/6 of TS-PCR neg samples only5353/098.177.43.80.020.830.2  0.0          Wistuba II*Cancer Res* (1997)USAFixed biopsiesSPF102020/090.060.020.0 5.05.0             Resnick RM*JNCI* (1990)USA (+Holland)Fixed biopsiesMy09/11, WD72/763329/4100.075.815.23.03.03.0      0.0      Pirog EC*Am J Pathol* (2000)USA (+Poland)Fixed biopsiesSPF10760/7589.539.538.210.51.31.30.02.70.00.00.00.00.00.00.0  0.0 **Region subtotal**    **15621112/45087.554.922.13.33.93.20.20.60.40.00.20.01.10.20.10.00.20.10.0**                          *South and Central America*Bosch FX*JNCI* (1995)Argentina,Bolivia,Brazil,Chile,Colombia,Cuba,Panama,ParaguayFresh biopsiesMY09/11505505/092.950.59.57.36.93.62.23.22.02.80.61.00.20.4 0.2   Alonio LV*MEDICINA* (2000)ArgentinaBiopsiesGP 5+/6+3030/093.346.720.0 3.33.3      6.7      Eluf-Neto J*Br J Cancer* (1994)BrazilExfol. cellsGP 5/6186186/084.453.89.7 2.23.2      0.0      Lorenzato F*Int J Gynecol Cancer* (2000)BrazilExfol. cellsMY09/115959/089.859.338.50.011.95.13.41.73.4   0.0      Rabelo-Santos SH*International Papillomavirus Conference Proceedings* (2000)BrazilFixed biopsiesGP 5+/6+5651/580.457.15.4 1.88.90.00.0 0.0 0.00.0      Munoz N*Int J Cancer* (1992)ColombiaExfol. cellsMY09/118787/072.450.65.7 5.70.0  3.4   0.0      Herrero R*JNCI* (2000)Costa RicaExfol. cellsMY09/11 +HMB013434/088.047.015.00.05.98.812.00.02.92.92.92.92.95.90.0 0.02.90.0Ferrera A*Int J Cancer* (1999)HondurasExfol. cellsMY09/1110499/580.647.113.55.83.89.66.71.00.01.00.00.01.00.00.00.00.00.00.0Torroella-Kouri M*Gynecol Oncol* (1998)MexicoFresh biopsies+Exfol. CellsMY09/11 +HMB016959/1087.042.014.510.12.90.04.32.90.04.31.40.00.01.44.31.40.01.41.4Meyer T*J Infect Dis* (1998)MexicoFresh biopsiesMY09/116060/096.743.316.73.323.36.70.01.71.70.01.70.03.30.01.73.30.00.00.0Illades-Aguiar B*International Papillomavirus Conference Proceedings* (2001)MexicoFresh biopsiesMY09/117466/897.360.810.80.010.81.44.12.70.00.00.00.01.40.00.00.00.00.0 Santos C*Br J Cancer* (2001)PeruFresh biopsiesGP5+/6+196171/2594.956.112.24.69.74.12.07.73.60.51.01.00.00.02.60.00.01.00.5Lo KWK*Int J Cancer* (2002)ChinaFresh biopsiesMY09/11, GP5+/6+809731/7883.766.96.30.40.61.53.22.2           Mortazavi SH*Asian Pacific J Cancer Prev* (2002)IranFixed biopsiesTS-PCR only6961/885.573.911.6  1.2                                       Ishikawa H*Cancer* (2001)JapanFixed biopsiesTS-PCR only5252/076.953.823.1  1.9             Dybikowska A*Oncol Rep* (2002)PolandExfol. cellsMY09/115353/053.848.10.0 1.91.91.9     0.0      Pegoraro RJ*Int J Gynecol Cancer* (2002)South AfricaFresh biopsiesMY09/11190190/098.446.814.24.7 101.11.61.6  0.00.5      Cuzick J*Br J Cancer* (2000)UKExfol. cellsMY09/1111685/319465.511.20.011.26.91.70.01.70.01.70.00.00.00.00.00.00.00.0**Region subtotal**    **14601407/5389.351.710.65.57.04.02.93.32.01.90.70.70.50.51.70.40.00.40.4**                          **Total**   **10 0588550/272586.051.016.34.43.93.82.72.30.90.80.60.50.60.50.40.20.20.20.2** 

[^1]: HPV=human papillomavirus; ICC=invasive cervical cancer; SCC=squamous cell carcinoma; ADC=adeno/adenosquamous carcinoma.

[^2]: Adjusted for histological type, region, HPV DNA specimen and PCR primers.
